Related by context. All words. (Click for frequent words.) 68 AGHD 67 Phase Ib study 66 Phase III randomized controlled 66 Velcade bortezomib 66 Spiegelmer ® 66 BRIM3 65 Onrigin 65 Azedra 65 MAGE A3 ASCI 64 PrevOnco 64 Phase Ib clinical 64 Solorel ® 64 phase IIb trial 64 Firazyr 64 omacetaxine mepesuccinate 64 trastuzumab DM1 T DM1 64 DCCR 64 OvaDx 64 Evoltra ® 64 EGS# 64 pharmacokinetic PK study 64 Vernakalant 64 CHAMPION PCI 64 preclinical efficacy 64 crizotinib PF # 64 bioequivalency 64 IL# PE#QQR 64 liposomal formulation 64 generation purine nucleoside 63 VIAject 63 Targretin capsules 63 Mipomersen 63 vemurafenib 63 Phase 1a clinical 63 IMPACT DCM 63 Arranon 63 Huntexil 63 CVac 63 Phase Ib II 63 ruxolitinib 63 ZOLINZA 63 Campath alemtuzumab 63 phase IIIb 63 reslizumab 63 Removab 63 Degarelix 63 trastuzumab DM1 63 inhaled AAT 63 Corlux 63 Pivotal Phase III 63 phase Ib 63 Phase lll 63 viral kinetics 63 Levetiracetam 62 TBC# 62 ATL# [001] 62 PMA submission 62 Amrubicin 62 Prostate AdenoCarcinoma Treatment 62 thorough QT 62 Phase #/#a 62 SNT MC# 62 R roscovitine 62 Phase #b/#a 62 novel oral anticoagulant 62 acyclovir Lauriad ® 62 dose escalation Phase 62 PROSTVAC ® 62 BAL# [002] 62 PSMA ADC 62 Dalbavancin 62 Zarnestra 62 BrachySil TM 62 ADVANCE PD 62 tipifarnib 62 Valdoxan 62 Urocidin 62 Androxal TM 62 Cloretazine 62 Elagolix 62 rALLy trial 62 Phase IIA 62 hepatitis B vaccine Heplisav 62 BLA filing 62 ALGRX 62 Glybera R 62 Aplidin 62 miglustat 62 dose escalation clinical 62 MAA submission 62 MAQC 62 CLIRS trial 62 DXL# 62 AeroLEF TM 62 Cloretazine ® 62 Quinamed 62 Medidur TM FA 62 Evoltra 62 phase IIb clinical 62 IND submission 62 novel histone deacetylase 62 budesonide foam 61 EOquin TM 61 Alvesco R 61 lumiliximab 61 HoFH 61 Genz # 61 GLP toxicology studies 61 BRAF inhibitor 61 ARIKACE ™ 61 Phase #b/#a trial 61 MERLIN TIMI 61 phase IIa clinical 61 ONGLYZA ™ 61 budesonide MMX 61 hoFH 61 tesmilifene 61 eculizumab therapy 61 Omapro 61 sorafenib Nexavar 61 ongoing Phase 1b 61 Rasagiline 61 refractory chronic lymphocytic 61 genomic biomarker 61 Zemplar Capsules 61 Solorel TM 61 ospemifene 61 OncoVEX 61 Safinamide 61 Clinicaltrials.gov 61 Q#IR 61 Pazopanib 61 HuMax CD4 61 BRIM2 61 eosinophilic asthma 61 vidofludimus 61 histone deacetylase HDAC inhibitor 61 multicentre randomized 61 XL# SAR# 61 RezularTM 61 relapsed MM 61 fidaxomicin Phase 61 OvaRex ® MAb 61 phase IIa 61 Vicriviroc 61 Anavex #-# 61 Pertuzumab 61 IMA# 61 pharmacokinetic PK profile 61 dasatinib Sprycel 61 AZILECT ® 61 CIP TRAMADOL ER 61 tolevamer 61 PEGylated interferon 61 EOquin 61 Telatinib 61 Temsirolimus 61 Silodosin 61 CEQ# 61 multicenter multinational 61 pivotal bioequivalence 61 Gleevec resistant 61 Epirubicin 61 Dacogen injection 61 dalbavancin 61 Phase IIB 61 Aryplase 61 Civacir 61 Zenvia Phase III 61 multicenter randomized Phase 61 mertansine 61 YONDELIS 61 Phase IIIb clinical 60 trastuzumab emtansine T DM1 60 randomized controlled Phase 60 PEG IFN 60 rALLy 60 pharmacokinetic PK 60 multicenter Phase II 60 sNDA submission 60 midstage trials 60 ganetespib 60 Orazol 60 romidepsin 60 Phenoptin 60 Phase IIb clinical trials 60 RhuDex 60 Zybrestat 60 HCl capsules 60 Erlotinib 60 Cinquil 60 teriflunomide 60 oral renin inhibitor 60 Dacogen decitabine 60 GALNS 60 Glybera 60 tafamidis 60 thalidomide Thalomid 60 MoxDuo IR 60 ORMD 60 mg/m2 cohort 60 PrevOnco ™ 60 Troxatyl 60 Provenge prostate cancer 60 Insulin PH# 60 MYDICAR 60 PROSTVAC TM 60 INCB# [001] 60 Nexavar sorafenib 60 randomized multicenter Phase III 60 DEB# 60 methylnaltrexone 60 acyclovir Lauriad R 60 GRNVAC1 60 anidulafungin 60 riociguat 60 AmpliChip 60 dosing cohort 60 KRN# 60 Archexin 60 Orathecin 60 ROCKET AF 60 galiximab 60 recurrent GBM 60 baminercept 60 Randomized Phase II 60 Pafuramidine 60 RhuDex R 60 paclitaxel poliglumex 60 alvespimycin 60 Plenaxis TM 60 Hycamtin ® 60 Ceflatonin 60 biliary tract cancer 60 UPLYSO 60 R#/MEM # 60 Vectibix panitumumab 60 AERx iDMS 60 Allovectin 7 60 DCVax Brain 60 cinacalcet 60 Kynapid 60 phase IIb study 60 oral ridaforolimus 60 balsalazide tablet 60 VIAject R 60 BNC# 60 icatibant 60 Pivotal Study 60 midstage clinical 60 CCR5 antagonist 60 Acute Decompensated Heart Failure 60 huN# DM1 60 Zingo TM 60 Annamycin 60 CRMD# 60 PDE4 inhibitor 60 histone deacetylase inhibitor 60 AVERROES 60 elacytarabine 60 Decitabine 60 Clevudine 60 PIX# trial 60 alemtuzumab MS 60 Onconase 60 OvaRex R 60 ZACTIMA 60 metastatic malignant 60 lomitapide 60 Phase IIIb study 60 relapsed MCL 60 REMINYL ® 60 brivanib 60 PROVENGE sipuleucel T 60 Actimmune ® 60 fosbretabulin 60 Achieves Primary Endpoint 60 Pemetrexed 60 Dasatinib 60 XOMA 3AB 60 HuMax EGFr 60 Premarket Approval 60 VIR# 60 gastrointestinal stromal tumors GIST 60 ixabepilone 60 photoprotective drug 60 Specifid 59 Saforis 59 Dendreon Provenge 59 IPLEX 59 Premarket Approval Application 59 Sipuleucel T 59 tanespimycin 59 LCP AtorFen 59 Phase IIa trial 59 GAMMAGARD 59 Gleevec imatinib mesylate 59 Zavesca R 59 liposomal amphotericin B 59 randomized Phase IIb 59 Riluzole 59 TYGACIL 59 anticancer compound 59 MabThera rituximab 59 PC DAC Exendin 59 LAF# 59 STRIDE PD 59 Plicera 59 CAMMS# 59 radiation sensitizer 59 T Pred 59 ACCEDE 59 FOLOTYN ® 59 PF # [002] 59 maximally tolerated dose 59 Aflibercept 59 Phase III psoriasis 59 oral methylnaltrexone 59 p# biomarker 59 HIV integrase inhibitor 59 pediatric acute lymphoblastic 59 solithromycin 59 HCV replicon 59 Avastin bevacizumab 59 EmbraceAC 59 Pivotal Phase 59 BEXXAR 59 registrational trial 59 Phase IIa trials 59 Camvia 59 Prosaptide 59 PRIMO CABG 59 MoxDuo ® IR 59 Omnitarg 59 CIP ISOTRETINOIN 59 seliciclib CYC# 59 vernakalant hydrochloride 59 RSR# 59 Cimzia ® certolizumab pegol 59 Saxagliptin 59 paclitaxel Taxol R 59 torezolid phosphate 59 Thrombin 59 VitiGam 59 sargramostim 59 OncoVEX GM CSF 59 ATL# [002] 59 Files Investigational 59 Etravirine 59 malignant ascites 59 Talotrexin 59 refractory CLL 59 SPRYCEL ® 59 antiangiogenic agent 59 etanercept Enbrel 59 severe hypercholesterolemia 59 Heplisav 59 receptor tyrosine kinase inhibitor 59 NSABP B 59 Capesaris 59 Phase III Clinical Trial 59 vascular disrupting agent 59 Initiate Phase 59 IMC #B 59 Phase III Clinical Trials 59 preclinical pharmacokinetic 59 refractory APL 59 AVADO 59 JAK inhibitor 59 G#DT 59 CIMZIA ™ 59 Sprycel dasatinib 59 chronic idiopathic thrombocytopenic purpura 59 ATPace TM 59 CCX# 59 Trofex 59 Nuvion 59 Iluvien ® 59 Zoraxel 59 PEG SN# 59 rilonacept 59 elotuzumab 59 Phase 2b Study 59 Bezielle 59 confirmatory Phase 59 DermaVir Patch 59 PEARL SC 59 pramlintide metreleptin 59 IMPACT IMmunotherapy 59 PCA3 test 59 Tesmilifene 59 Ataluren 59 Prodarsan ® 59 Matrix Phase 2b 59 azilsartan medoxomil 59 trastuzumab Herceptin ® 59 Insulin Delivery Systems 59 somatostatin analogue 59 ENMD # 59 Meets Primary Endpoint 59 Alzhemed TM 59 Japanese Encephalitis vaccine 59 dose escalation phase 59 PSN# [002] 59 Natalizumab 59 ELIQUIS 59 registrational 59 mTOR inhibitor 59 injectable formulations 59 Accelerated Approval 59 Phase #b/#a clinical 59 HEPLISAV ™ 59 Cancidas 59 MyVax 59 INT# [002] 59 randomized blinded 59 aleglitazar 59 TRX1 59 controlled multicenter Phase 59 NovoTTF 59 liprotamase 59 Tarceva TM 59 Lisofylline LSF 59 sitaxsentan 59 IIa trial 59 KNS # 59 trastuzumab Herceptin 59 pomalidomide 59 Elitek 59 CAPHOSOL 59 Neuvenge 59 Initiated Phase 59 Epanova 59 fidaxomicin Phase 3 59 PI3K/Akt pathway inhibitor 59 TASKi3 59 Muraglitazar 59 M Vax 59 Vertex hepatitis C 59 Renal Cell Carcinoma RCC 59 VEGF inhibitor 59 CA9 SCAN 59 Kahalalide F 59 ORENCIA ® 59 oral taxane 59 enzastaurin 59 AP# [003] 59 MEND CABG II 59 SUTENT ® 59 Glucophage XR 58 VersaFilm 58 LUMINATE 58 CCR5 inhibitor 58 RhuDex ® 58 Panzem NCD 58 Cethromycin 58 Gamunex C 58 MGd 58 Roflumilast 58 subcutaneously administered 58 OMAPRO 58 CoFactor 58 AFREZZA TM 58 BR.# 58 E1 INT TM 58 Linjeta 58 Biologic License Application BLA 58 Noxafil 58 SIR Spheres 58 clinical pharmacology studies 58 Maribavir 58 intravenous dosing 58 Stedesa 58 phase IIb 58 ACE Inhibitor 58 double blinded placebo 58 Xanafide 58 Phase III ThermoDox 58 nucleotide analogue 58 Sapacitabine 58 pertuzumab 58 randomized Phase 2b 58 Alequel 58 adecatumumab MT# 58 Vidaza azacitidine 58 HyQ 58 Cervista HPV HR 58 sipuleucel T 58 Laquinimod 58 Cologuard 58 briakinumab 58 Eniluracil 58 Pimavanserin 58 Fabry Disease 58 intravenous methylnaltrexone 58 genotypic resistance 58 Xelox 58 ANCHOR trial 58 Reverset 58 trabectedin 58 CLARITY study 58 Twinrix 58 HDL Selective Delipidation 58 ACAPODENE 58 Ambrisentan 58 Ranolazine 58 Randomised 58 intranasal formulation 58 BrachySil 58 Octreolin 58 desvenlafaxine 58 Octreotide 58 refractory prostate cancer 58 Bortezomib 58 randomized multicenter trial 58 NADiA ProsVue 58 Zolinza 58 Trastuzumab DM1 58 bicifadine 58 Soliris eculizumab 58 SEPET TM 58 Alocrest 58 GLP1 agonist 58 DPP4 58 PANVAC VF 58 OHR/AVR# 58 alefacept 58 EXPAREL TM 58 Certican 58 Aurora Kinase 58 Neurodex 58 Tumor Response 58 gemcitabine Gemzar ® 58 Hydroxyurea 58 IND Application 58 KRAS mutation 58 RE LY trial 58 IGF 1R inhibitor 58 non nucleoside inhibitor 58 miconazole Lauriad ® 58 AEGR 58 ADAGIO study 58 Verigene System 58 Sym# 58 metastatic castrate resistant 58 regorafenib 58 Ocrelizumab 58 Arzerra ofatumumab 58 nonsmall cell lung cancer 58 Phase IIb III 58 Hycamtin 58 CUSTOM III 58 ImClone Erbitux 58 EndoTAG TM -1 58 Phase 1b clinical 58 HQK 58 OraTest 58 postapproval 58 Guanilib 58 radezolid 58 Bayer HealthCare Onyx Pharmaceuticals 58 Toctino ® alitretinoin 58 IIa trials 58 Asentar 58 Kombiglyze XR 58 Danazol 58 Cardiotoxicity 58 Phase IIIb 58 tocilizumab 58 GSK# [002] 58 Fibrillex 58 Iloperidone 58 farletuzumab 58 Eltrombopag 58 NOX E# 58 Multiple Ascending Dose 58 LungSign TM 58 Carfilzomib 58 Personalized Immunotherapy 58 neratinib 58 GW# [003] 58 TLK# 58 eliglustat tartrate 58 CLIRS 58 Complete Response 58 ATIR 58 Cimzia TM 58 immunotherapeutic vaccine 58 Fodosine 58 Ozarelix 58 HuMax CD# 58 APTIVUS 58 ATL/TV# 58 Phase 2b study 58 Iluvien TM 58 FIRMAGON R 58 DACH platinum 58 PTK# 58 CYT# QbG# 58 Virulizin 58 decitabine 58 Non inferiority 58 maturation inhibitor 58 orBec 58 forodesine 58 CaPre TM 58 Argatroban 58 Azacitidine 58 CyPath ® 58 recurrent metastatic 58 Traficet EN 58 favorable pharmacokinetic profile 58 protease inhibitor PI 58 multicenter randomized placebo controlled 58 pharmacodynamic PD 58 ORENCIA R 58 rhIGF-I/rhIGFBP-3 58 Bosentan 58 Zerenex Phase 58 beta 1a 58 pharmacokinetics PK 58 Teysuno 58 Posiphen 58 Vion Pharmaceuticals 58 Vilazodone 58 hormone agonist 58 masitinib 58 EDEMA3 58 Phase IIb trials 58 HDAC Inhibitor 58 Trobalt 58 divalproex sodium 58 preclinically 58 SUCCEED trial 58 trodusquemine 58 Genentech Rituxan 58 Oxytrex TM 58 Ampligen r 58 CAELYX 58 human microdosing 58 ProSavin 58 QNEXA 58 Rezular 58 daptomycin 58 Nuedexta 58 Technosphere Insulin 58 EP #R 58 Arcalyst 58 pan HDAC inhibitor 58 non nucleoside 58 HCV RESPOND 2 57 GSK# [001] 57 thymalfasin 57 OncoVex 57 Ceflatonin ® 57 Egrifta 57 Oncotype DX colon cancer 57 Thorough QT 57 PhG alpha 1 57 sNDA filing 57 Zenapax 57 OncoGel 57 Actilon 57 LUX Lung 57 NeuVax 57 CIMZIA TM certolizumab pegol 57 CANCIDAS 57 UroVysion 57 StemEx R 57 Phase 2a clinical trials 57 clevidipine 57 Initiate Clinical Trial 57 PET tracers 57 bortezomib Velcade 57 CALGB # [002] 57 Denufosol 57 PREOS R 57 dose cohort 57 pralatrexate injection 57 NVA# 57 buccal spray 57 vinflunine 57 NN# [001] 57 maribavir 57 Completes Patient Enrollment 57 proteomic biomarkers 57 APEX PD 57 Centralized Procedure 57 JZP 57 BETAS 57 AZILECT R 57 Phase 2b Clinical Trial 57 Phase 2b trial 57 octreotide acetate 57 Icatibant 57 Dyloject TM 57 JAK Inhibitor 57 Omacetaxine 57 standard chemotherapy regimen 57 MIRCERA 57 Ophena TM 57 Zirgan 57 Mylotarg 57 otelixizumab 57 RAPAFLO 57 blinded randomized 57 Retacrit 57 Dabigatran etexilate 57 CCR5 receptor antagonist 57 subcutaneous methylnaltrexone 57 alvimopan 57 TKM ApoB 57 pain palliation 57 Blinatumomab 57 oral rivaroxaban 57 TRIST study 57 APTIMA HPV assay 57 oral prodrug 57 PLK1 SNALP 57 orally dosed 57 Prodarsan R 57 Phase III 57 indibulin 57 Acthar Gel 57 TransMID 57 MoxDuo TM IR 57 OLYMPIA registry 57 placebo controlled Phase 57 bendamustine 57 nonclinical studies 57 ataluren 57 Tesetaxel 57 IND Investigational New 57 interferon beta 1b 57 Zenvia ™ 57 Carbaglu 57 StemEx 57 Darusentan 57 RE LY 57 Panzem 57 Amgen denosumab 57 TMC# [002] 57 autologous cellular immunotherapy 57 wilate ® 57 Diamyd r 57 xanthine oxidase inhibitor 57 Triolex 57 Pharmacokinetics PK 57 anti CD# antibodies 57 Telbivudine 57 Telavancin 57 XYOTAX TM 57 guanfacine extended release 57 Lupuzor 57 pharmacokinetic studies 57 Study GL# 57 Zavesca r 57 casopitant 57 Oncotype 57 placebo controlled clinical 57 Dapagliflozin 57 Novartis Zometa 57 Vpriv 57 Rigel R# 57 Treanda 57 metastatic hormone refractory 57 Abiraterone 57 gefitinib Iressa 57 Tasigna nilotinib 57 ITAX 57 Actemra tocilizumab 57 CHOP chemotherapy 57 virus HCV protease inhibitor 57 BAY #-# 57 Zemiva 57 Myocet 57 monoclonal antibody therapeutics 57 Prolor 57 RAPTIVA 57 Raptiva ® 57 terlipressin 57 subcutaneous formulation 57 ACZ# 57 Zavesca 57 Anacetrapib 57 NeuroSTAT ® 57 ponatinib 57 ceftazidime 57 MyVax R 57 miRNA biomarkers 57 LibiGel ® 57 Triapine R 57 Cloretazine R VNP#M 57 Targretin 57 LidoPAIN SP 57 inhibitor RG# 57 vorinostat 57 Enzastaurin 57 Phase III ADT 57 oral PTH 57 Tanespimycin 57 Cleviprex TM clevidipine 57 GRN# 57 Golimumab 57 Gleevec Glivec 57 topical formulation 57 Candesartan 57 pitavastatin 57 BYDUREON ™ 57 Deferiprone 57 LEVADEX ™ 57 Xinlay 57 phase Ib clinical 57 radioimmunotherapy RIT 57 adalimumab Humira 57 Byetta LAR 57 nucleotide analog 57 Pivotal Trial 57 cannabinor 57 eribulin mesylate 57 axitinib 57 BRILINTA 57 unblind 57 vivo potency 57 KB# [002] 57 Serada 57 PHX# 57 deferiprone 57 mCRC patients 57 orally inhaled migraine 57 ganaxolone 57 Esbriet pirfenidone 57 rxRNA 57 brivaracetam 57 Febuxostat 57 FDA Accepts 57 successfully commercialize Iluvien 57 JAK3 inhibitor 57 Tracleer R 57 leukemia AML 57 prospective multicenter 57 mg/m2 dose 57 multicenter randomized controlled 57 vismodegib 57 including eniluracil ADH 57 Sutent sunitinib 57 phase 2a 57 PFO migraine 57 RIGScan CR 57 interferon gamma 1b 57 Phase 2a trial 57 clofarabine 57 Revlimid lenalidomide 57 APPRAISE 57 small molecule tyrosine 57 Trandolapril 57 CINQUIL 57 Fentanyl TAIFUN R 57 Ophena 57 GV# [001] 57 humanised antibody 57 CRLX# 57 aurora kinase 57 Proxinium TM 57 HCV SPRINT 57 pegylated interferon alpha 57 ToGA 57 T#I [002] 57 retapamulin 57 BFPET 57 intravenous cyclophosphamide 57 PNP inhibitor 57 Biologic License Application 57 Trofile assay 57 Femara letrozole 57 MK #B 57 LEP ETU 57 HuLuc# 57 UCB Cimzia 57 Tykerb lapatinib 57 AKT inhibitor 57 ofatumumab HuMax CD# 57 R#/MEM 57 Evamist TM 57 Restanza 57 transcranial Doppler ultrasound 57 cathepsin K inhibitor 57 octreotide implant 57 ularitide 57 pancreatic enzyme replacement 57 Successfully Completes Phase 57 Valtropin 57 Tolvaptan 57 relapsing multiple sclerosis 57 chest radiographs 57 Bevacizumab 57 Glufosfamide 57 Evoltra R 57 Herceptin trastuzumab 57 assessing T DM1 57 HCV protease inhibitors 57 acetonide FA 57 lorvotuzumab mertansine 57 heFH 57 invasive candidiasis 57 Clolar 57 tramiprosate Alzhemed TM 57 Pirfenidone 57 LymphoStat B TM 57 Xcellerated T Cells 57 RSD# 57 afamelanotide 57 CRp 57 Zilver PTX stent 57 Advexin 57 erlotinib Tarceva ® 57 Fulvestrant 57 Inc. Amex SYI 57 pegylated interferon alfa 57 Rhucin R 57 dorzolamide 57 Loramyc R 57 Edurant 57 NOD mouse 57 Randomized Evaluation 57 tumor histology 57 eltrombopag 57 volociximab 57 selective modulator 57 depsipeptide 57 LAS# [002] 57 Neugene 57 canagliflozin 57 PD LID 57 clobazam 56 Initiates Clinical 56 lorcaserin Phase 56 DDP# 56 davunetide intranasal AL 56 Gattex 56 delafloxacin 56 HuCAL antibodies 56 micafungin 56 Pruvel 56 Roche Herceptin 56 relapsed refractory multiple myeloma 56 Betaferon ® 56 GnRH antagonist 56 bardoxolone 56 Virulizin ® 56 Rilutek 56 UVIDEM 56 eTag assays 56 QLT# 56 OPAXIO 56 arzoxifene 56 chemotherapeutic regimen 56 Varespladib 56 FDG-PET/CT 56 K ras mutations 56 evaluating tivozanib 56 Liposomal 56 oral FTY# 56 corticosteroid dexamethasone 56 ONTAK 56 OMAPRO ™ 56 Randomized Phase 56 Antigen CEA 56 Anturol TM 56 busulfan 56 Entecavir 56 illumigene C. difficile 56 MoxDuo ® 56 dopamine partial agonist 56 MEVACOR 56 EndoTAGTM 1 56 VIAject ™ 56 Fast Track Status 56 GeoVax vaccine 56 RSD# oral 56 ILUVIEN ® 56 GEM OS1 56 polymerase inhibitor 56 investigational humanized monoclonal antibody 56 XmAb# 56 Corus CAD 56 Metastatic Melanoma 56 BiTE 56 ChronVac C R 56 acute mania 56 Trovax 56 anti angiogenic agent 56 pharmacokinetic characteristics 56 ChemoFx 56 Daclizumab 56 pharmacodynamic properties 56 optimal dosing regimens 56 PREGNANT Study 56 Talabostat